Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | TEK | Q02763 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.46 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15723893 | 0.86 | CLK4 (0.55) | RAB9ACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL15723965 | 0.86 | GSTP1 (0.47) | CYP11B2CYP17A1RAB9ACYP11B1CYP19A1 | |
| SCHEMBL15730178 | 0.82 | CYP11B2 (0.56) | CYP11B2CYP17A1RAB9ACYP11B1CYP19A1 | |
| SCHEMBL624353 | 0.81 | CYP11B2 (0.57) | CYP11B2CYP17A1RAB9ACYP11B1CYP19A1 | |
| SCHEMBL18852464 | 0.78 | RAB9A (0.43) | CYP11B2RAB9ACYP11B1CYP1A2CYP3A4 | |
| SCHEMBL15723922 | 0.78 | PIK3CD (0.50) | CYP11B2CYP17A1CYP11B1CYP19A1CYP1A2 | |
| SCHEMBL25502013 | 0.77 | PTGS2 (0.71) | CYP11B2CYP17A1RAB9ACYP11B1CYP19A1 | |
| SCHEMBL15723912 | 0.77 | ALDH1A1 (0.50) | RAB9ACYP1A2CYP2C19NPC1 | |
| SCHEMBL15723963 | 0.77 | RAB9A (0.62) | RAB9ACYP1A2CYP3A4CYP2C19NPC1 | |
| SCHEMBL15723903 | 0.75 | TGFBR1 (0.44) | RAB9ACYP1A2NPC1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9540343-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CYP11B2 50/4885CYP17A1 77/4885RAB9A 357/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | CYP11B2 50/4885CYP17A1 77/4885RAB9A 357/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | CYP11B2 50/4885CYP17A1 77/4885RAB9A 357/4885 |
| US-20170137405-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CYP11B2 50/4885CYP17A1 77/4885RAB9A 357/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CYP11B2 50/4885CYP17A1 77/4885RAB9A 357/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | CYP11B2 50/4885CYP17A1 77/4885RAB9A 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.